Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer
NCT ID: NCT01254591
Last Updated: 2013-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
500 participants
INTERVENTIONAL
2006-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This clinical trial is studying PET/CT scanning before surgery in patients with non-small cell lung cancer, colorectal cancer, breast cancer, esophageal cancer, or head and neck cancer.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To determine the ability of preoperative fludeoxyglucose F 18 positron emission tomography/computed tomography (PET/CT) scanning in assessing tumor angiogenesis in patients with potentially operable non-small cell lung cancer, colorectal cancer, breast cancer, esophageal cancer, or head and neck cancer.
* To determine the ability of preoperative fludeoxyglucose F 18 PET/CT scanning in assessing prognosis by means of measuring angiogenesis in these patients.
OUTLINE: All patients undergo fludeoxyglucose F 18 positron emission tomography/computed tomography (PET/CT) scanning for staging, tumor perfusion measurement/angiogenesis, and glucose metabolism. If staging confirms operable disease, then the patient proceeds to surgery as planned. Resected tumor tissue samples are examined for tumor angiogenesis in the various cancer types.
Some patients undergo a half-dose of rubidium Rb-82 or 18F-fluoromisonidazole or \[18F\]-ML-10 PET scan or fluorescence angiography. Patients with colorectal cancer undergo a CT scan for perfusion of the tumor after the staging PET/CT. Patients with breast cancer undergo infrared thermometry as well as a MRI scan for staging and to predict angiogenesis.
After completion of study therapy, patients are followed up at 1 month and then every 6 months for 5 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
DIAGNOSTIC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
18F-fluoromisonidazole
fluorescence angiography
laboratory biomarker analysis
infrared thermography
magnetic resonance imaging
therapeutic conventional surgery
[18F]-ML-10
fludeoxyglucose F 18
rubidium Rb-82
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of non-small cell lung cancer, colorectal cancer, breast cancer, esophageal cancer, or head and neck cancer
* Potentially operable disease
* Hormone receptor status not specified
PATIENT CHARACTERISTICS:
* Not specified
* Menopausal status not specified
PRIOR CONCURRENT THERAPY:
* Not specified
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University College London (UCL) Cancer Institute
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Ell, MD
Role: PRINCIPAL_INVESTIGATOR
University College London Hospitals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University College Hospital
London, England, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Contact Person
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UCL-TUMOR-ANGIOGENESIS
Identifier Type: -
Identifier Source: secondary_id
EU-21086
Identifier Type: -
Identifier Source: secondary_id
CDR0000689973
Identifier Type: -
Identifier Source: org_study_id